Clinical trials in Oldenburg In Holstein – page 48

840 clinical trials in Oldenburg In Holstein, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Oldenburg In Holstein at a glance

840

clinical trials

Research sites1

Quick filters

840 trials in Oldenburg In Holstein

Open in trial search

Gastrooesophageal cancer

Not recruiting

Study on Atezolizumab with Drug Combination for Patients with Gastric Cancer and Esophagogastric Junction Adenocarcinoma

Registered drugNo placebo

Study on Atezolizumab with Drug Combination for Patients with Gastric Cancer and Esophagogastric Junction Adenocarcinoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Malignant melanoma

Not recruiting

Study of Nivolumab for Patients with High-Risk Stage II Melanoma After Surgery

Registered drugNo placebo

Study of Nivolumab for Patients with High-Risk Stage II Melanoma After Surgery

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Universitaetsklinikum Essen AöR

Contact Research Centre

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

Study on Itepekimab for Former Smokers with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational

Study on Itepekimab for Former Smokers with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Itepekimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Uveitis+1

Not recruiting

Study on Izokibep for Patients with Non-infectious Uveitis

Investigational

Study on Izokibep for Patients with Non-infectious Uveitis

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Izokibep
Sponsor:Acelyrin Inc.

Contact Research Centre

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:GBG Forschungs GmbH

Contact Research Centre

Chronic spontaneous urticaria

Not recruiting

Study of remibrutinib for long-term treatment of adult patients with chronic spontaneous urticaria who completed previous remibrutinib studies

Registered drug

Study of remibrutinib for long-term treatment of adult patients with chronic spontaneous urticaria who completed previous remibrutinib studies

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Remibrutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

B-cell lymphoma refractory

Not recruiting

Study on Tafasitamab with Gemcitabine, Oxaliplatin, and Rituximab for Patients with Aggressive B-cell Lymphoma

Registered drugNo placebo

Study on Tafasitamab with Gemcitabine, Oxaliplatin, and Rituximab for Patients with Aggressive B-cell Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Oxaliplatin
Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Contact Research Centre

Non-small cell lung cancer+1

Not recruiting

Study on Durvalumab and Chemotherapy for Patients with Resectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo

Study on Durvalumab and Chemotherapy for Patients with Resectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Universitaetsklinikum Essen AöR

Contact Research Centre

Giant cell arteritis

Not recruiting

Study on the Effectiveness and Safety of Secukinumab for Patients with New-Onset Giant Cell Arteritis in Clinical Remission

Registered drug

Study on the Effectiveness and Safety of Secukinumab for Patients with New-Onset Giant Cell Arteritis in Clinical Remission

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Secukinumab
Sponsor:Novartis Pharma GmbH

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study on JDQ443 for First-Line Treatment in Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer

InvestigationalNo placebo

Study on JDQ443 for First-Line Treatment in Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Sponsor:Novartis Pharma AG

Contact Research Centre

Cutaneous lupus erythematosus

Not recruiting

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Anifrolumab
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Oldenburg In Holstein

What the registry says about research in the country

01 Metabolic Disorders

Innovative clinical trials focusing on Type 2 Diabetes management and treatments, including studies of novel weekly insulin alternatives and oral medications for glycemic control.

Glycemic Control Studies
Insulin Alternatives Research
Cardiovascular Outcomes

Multiple studies evaluating new therapeutic approaches for better diabetes management and reducing cardiovascular risks.

02 Weight Management

Comprehensive research into obesity treatment and weight-related conditions, examining new therapeutic combinations and their effects on weight loss and associated health conditions.

Weight Loss Interventions
Obesity Medications
Comorbidity Management

Studies focusing on innovative approaches to weight management and treating obesity-related health complications.

03 Cardiovascular Health

Research examining treatments for atherosclerotic cardiovascular disease and related conditions, with emphasis on preventing major adverse cardiovascular events.

Cardiovascular Risk Reduction
Lipid Management
Preventive Therapies

Trials evaluating new medications for improving cardiovascular outcomes in high-risk patients.

04 Gastrointestinal Studies

Clinical investigations of treatments for Crohn's Disease and other digestive conditions, focusing on long-term efficacy and safety of new therapeutic approaches.

Inflammatory Bowel Disease
Long-term Treatment Outcomes
Disease Management

Studies aimed at improving quality of life for patients with chronic gastrointestinal conditions.

05 Oncology Research

Advanced studies in colorectal cancer treatment and management, including innovative approaches to Stage II and III cancer therapy.

Cancer Treatment Protocols
Disease-Free Survival
Adjuvant Therapy

Trials evaluating new treatment strategies for improving outcomes in cancer patients.

Back to Germany All countries